An article published online in AAOS Now summarizes an AAOS symposium on "Optimizing Clinical Use of Biologics in Orthopaedic Surgery," which was held Feb. 15-17, 2018. 

The writer notes that a preponderance of unproven and poorly described stem cell treatments marketed to consumers raises concerns for public health and safety. Among other things, symposium attendees agreed on a need to standardize and clarify terminology, including the definition of the term "stem cell." Participants also formed work groups to recommend candidate biologic targets and clinical outcome metrics to include imaging metrics for treatment of chronic tendon injuries, acute ligament and muscle injuries, knee osteoarthritis, and surgical soft-tissue repair. Learn more...

Comments (0)

There are no comments posted here yet

Submit Community Content

If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!